• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Entera Bio Ltd.

    11/14/25 4:06:29 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Entera Bio Ltd.

    (Name of Issuer)


    Ordinary shares, par value NIS 0.0000769 per share

    (Title of Class of Securities)


    M40527109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    M40527109


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,183,116.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,183,116.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,183,116.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    M40527109


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,183,116.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,183,116.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,183,116.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.6 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    M40527109


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,183,116.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,183,116.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,183,116.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Entera Bio Ltd.
    (b)Address of issuer's principal executive offices:

    KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), of Entera Bio Ltd. (the "Issuer") held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Ordinary Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Ordinary Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Ordinary shares, par value NIS 0.0000769 per share
    (e)CUSIP No.:

    M40527109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Ordinary Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Ordinary Shares reported herein.
    (b)Percent of class:

    2.6%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:11/14/2025
    Get the next $ENTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Entera Bio with a new price target

    B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

    6/16/21 6:22:06 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aegis Capital initiated coverage on Entera Bio with a new price target

    Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

    3/22/21 10:40:44 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group reiterated coverage on Entera Bio with a new price target

    Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

    3/11/21 12:09:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

    JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below. 7th Annual Evercore ISI HealthCONx Conference (Fireside Chat and 1x1 Meetings) Date and Time: December 3 at 9:10-9:30AM in Sevilla A Location: In person, December 3-5, 2024 Coral Gables, Florida A live webcast of the discussion will be available at the link below. A replay will remain accessible for 90 days following th

    11/18/25 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

    FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today reported fin

    11/14/25 4:05:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

    Consistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic treatment option that could dramatically expand patient access to bone-building therapy Entera Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence JERUSALEM, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported new clinical data from a post-hoc analysis of its Phase 2 trial of EB613, at the 2025 North American Menopause Society

    10/23/25 8:50:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/16/24 8:00:12 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    1/11/24 6:14:57 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lieberman Gerald M bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 12% to 226,961 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    12/27/23 5:00:37 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Toledano Miranda Jayne was granted 180,702 units of Ordinary Shares, increasing direct ownership by 77% to 415,575 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:37:05 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief of R&D Burshtein Gregory was granted 26,316 units of Ordinary Shares, increasing direct ownership by 35% to 101,442 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:35:58 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Yaacov-Garbeli Dana was granted 26,316 units of Ordinary Shares (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    7/18/25 4:34:36 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Entera Bio Ltd.

    10-Q - Entera Bio Ltd. (0001638097) (Filer)

    11/14/25 4:11:50 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Entera Bio Ltd. (0001638097) (Filer)

    11/14/25 4:06:59 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Entera Bio Ltd.

    SCHEDULE 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    11/14/25 4:06:29 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Leadership Updates

    Live Leadership Updates

    View All

    Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

    JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

    5/9/25 4:05:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

    JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

    5/15/24 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

    JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

    6/7/23 7:30:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Financials

    Live finance-specific insights

    View All

    Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

    JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

    11/10/22 4:15:00 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

    Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

    5/12/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entera Bio to Report First Quarter 2022 Financial Results on May 12

    BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

    4/28/22 8:00:00 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    11/20/24 1:48:55 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    8/20/24 6:01:17 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    1/16/24 10:45:49 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care